NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

Leukemia

Volumn 24, Issue 12, 2010, Pages 2023-2031

  Clappier, E ^a   Collette, S ^b   Grardel, N ^c   Girard, S ^d   Suarez, L ^a   Brunie, G ^a   Kaltenbach, S ^a   Yakouben, K ^a   Mazingue, F ^e   Robert, A ^f   Boutard, P ^g   Plantaz, D ^h   Rohrlich, P ⁱ   Van Vlierberghe, P ^j   Preudhomme, C ^c   Otten, J ^k   Speleman, F ^j   Dastugue, N ^f   Suciu, S ^b   Benoit, Y ^l   Bertrand, Y ^m   Cave H ^a   more..

^a HÔPITAL ROBERT DEBRÉ   (France)

^b EORTC DATA CENTER   (Belgium)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f CHU PURPAN   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^l GHENT UNIVERSITY   (Belgium)

^m UNIVERSITÉ LYON 1   (France)

more..

Author keywords

FBXW7; NOTCH1; pediatric leukemia; prognosis; T ALL

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; F BOX PROTEIN; FBXW7 PROTEIN; METHOTREXATE; NOTCH1 RECEPTOR; PREDNISOLONE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE ACTIVATION; GENE MUTATION; GENETIC SCREENING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 78650311120     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.205     Document Type: Article

References (43)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
3. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 2006; 20: 1496-1510.
4. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380-390.
5. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
6. Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, Dombret H et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106: 274-286.
7. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
8. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613.
9. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283-2291.
10. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781-785.
11. Aster JC, Xu L, Karnell FG, Patriub V, Pui JC, Pear WS. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol 2000; 20: 7505-7515.
12. Allman D, Karnell FG, Punt JA, Bakkour S, Xu L, Myung P et al. Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J Exp Med 2001; 194: 99-106.
13. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459: 1000-1004.
14. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, Six E et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem 2001; 276: 34371-34378.
15. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204: 1813-1824.
16. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
17. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966-971.
18. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14: 2257-2266.
19. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2004; 103: 442-450.
20. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of CancerFChildhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
21. Cave H, Guidal C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 1994; 83: 1892-1902.
22. Guidal C, Vilmer E, Grandchamp B, Cave H. A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2002; 16: 762-764.
23. Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003; 102: 1000-1006.
24. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
25. Renneville A, Kaltenbach S, Clappier E, Collette S, Micol JB, Nelken B et al. Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia 2010; 24: 476-480.
26. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008; 22: 124-131.
27. Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, Romany C et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.
28. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
29. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157.
30. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009; 113: 3918-3924.
31. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27: 4352-4356.
32. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003; 40: 274-280.
33. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JGCAM, Kooi C et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010 (this issue).
34. Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu J et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006; 12: 3043-3049.
35. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616.
36. Kox C, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Köhler R et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-cell acute lymphoblastic leukemia can be separated from NOTCH pathway activation by FBXW7 loss of function. Leukemia 2010 (this issue).
37. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809-3817.
38. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129: 734-745.
39. Demarest RM, Ratti F, Capobianco AJ. It's T-ALL about Notch. Oncogene 2008; 27: 5082-5091.
40. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009; 114: 1053-1062.
41. Deftos ML, He YW, Ojala EW, Bevan MJ. Correlating notch signaling with thymocyte maturation. Immunity 1998; 9: 777-786.
42. Sade H, Krishna S, Sarin A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004; 279: 2937-2944.
43. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorti-coid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50-58.